CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at Citizens Jmp

CRISPR Therapeutics (NASDAQ:CRSP) had its price target decreased by equities researchers at Citizens Jmp from $86.00 to $80.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 52.24% from the company’s previous close.

CRSP has been the subject of several other research reports. Royal Bank Of Canada lifted their price target on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 11th. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a report on Friday. Chardan Capital decreased their price target on CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating on the stock in a research note on Wednesday, November 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company set a $75.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, October 13th. Twelve equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $67.85.

CRISPR Therapeutics Stock Down 2.1%

Shares of CRSP stock opened at $52.55 on Friday. The firm has a fifty day moving average of $55.08 and a 200-day moving average of $58.28. The company has a market capitalization of $5.01 billion, a price-to-earnings ratio of -9.54 and a beta of 1.70. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million. On average, equities analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 60,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the transaction, the chief executive officer owned 134,201 shares of the company’s stock, valued at approximately $8,082,926.23. This represents a 30.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Thurston Springer Miller Herd & Titak Inc. grew its holdings in shares of CRISPR Therapeutics by 196.9% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares during the period. Atlantic Union Bankshares Corp purchased a new position in CRISPR Therapeutics during the second quarter worth about $33,000. Thompson Investment Management Inc. purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $33,000. Optiver Holding B.V. raised its position in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after purchasing an additional 210 shares during the period. Finally, Strategic Advocates LLC acquired a new position in CRISPR Therapeutics during the third quarter worth $34,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.